 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Resveratrol
|
|
Other Names:
|
trans-3,4',5-trihydroxystilbene
|
|
Therapy Types:
|
nutraceutical
|
|
Mechanisms:
|
neuroprotectant
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Phase III
|
|
Primary Medical Role:
|
Resveratrol is a polyphenolic compound in grapes and wine.
While levels of resveratrol in wine varies, it is
generally more abundant in red grapes and red wine.
Resveratrol intake has demonstrated in vivo protective
properties against multiple illnesses, including cancer,
cardiovascular disease, and ischemia, and was also found to
confer resistance to stress and to extend life span (Baur JA,
Sinclair DA, 2006). Also, see excellent reviews on the
cardioprotective effects of grape polyphenols (Leifert &
Abeywardena, 2008; Dohadwala & Vita, 2009).
|
|
Role in Alzheimer's Disease:
|
Blass and Gordon (2004) have demonstrated positive effects
in AD with an oral preparation of combined glucose, malate
and resveratrol. Glucose is the physiological precursor of
the substrates of oxidative metabolism in the brain, malate
is a primer of the energy-providing Krebs-cycle. Glucose and
malate therefore can provide reducing equivalents
(electrons) to regenerate the reduced form of resveratrol,
and do so under the normal regulation of brain cell
metabolism. Resveratrol has been shown to lower the levels
of secreted and intracellular amyloid-beta (Abeta) peptides
produced from different cell lines by promoting
intracellular degradation of Abeta via a mechanism that
involves the proteasome (Marambaud et al, 2005).
Resveratrol, a SIRT1 activating agent, has been shown to
promote neuronal survival. Resveratrol may also enhance the
gene expression of antioxidative genes and promote DNA
repair by stimulating the deacetylation of forkhead FOXO3/4
transcription factors (Kim et al, 2007).
|
|
Notes:
|
A phase III clinical trial to test the combination of
resveratrol, glucose and malate vs placebo in a randomized,
double-blind, placebo-controlled multi-site
study sponsored by the Department of Veterans Affairs is
currently recruiting participants. See NCT00678431
for further details. Contact: Amanda Burden at (212)
659-8883 or amanda.burden@mssm.edu
A phase III trial to test Longevinex brand resveratrol,
which also contains quercetin, rice bran, vitamin D and
ferulate has been announced by Medical College of Wisconsin,
but is not yet open for participant recruitment. See NCT00743743
for further details.
A Phase IV study to examine the effects of resveratrol in
mild cognitive impairment is sponsored by Charite
University, Berlin, Germany, and is currently recruiting
participants. See NCT01219244
for further details.
This record was last updated November 29, 2010.
|
Dohadwala MM, Vita JA. Grapes and cardiovascular disease. J
Nutr. 2009 Sep;139(9):1788S-93S. Abstract
Leifert WR, Abeywardena MY. Cardioprotective actions of
grape polyphenols. Nutr Res. 2008 Nov;28(11):729-37. Abstract
Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F,
Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM,
Puigserver P, Sinclair DA, Tsai LH. SIRT1 deacetylase
protects against neurodegeneration in models for Alzheimer's
disease and amyotrophic lateral sclerosis. EMBO J. 2007 Jul
11;26(13):3169-79. Abstract
Baur JA, Sinclair DA. Therapeutic potential of resveratrol:
the in vivo evidence. Nat Rev Drug Discov. 2006
Jun;5(6):493-506. Abstract
Marambaud P, Zhao H, Davies P. Resveratrol promotes
clearance of Alzheimer's disease amyloid-beta peptides. J
Biol Chem. 2005 Nov 11;280(45):37377-82. Abstract
|
|
|
|
|
Home
